China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing for its drug candidate HSK16149, intended for the treatment of diabetic peripheral neuropathic pain (DPNP), has been accepted for review by the National Medical Products Administration (NMPA). HSK16149 is an in-house Category 1 drug being developed to treat DPNP and post-herpes neuralgia.
HSK16149 Profile
Preclinical studies of HSK16149 have demonstrated that the molecule should achieve strong and long-acting analgesic effects with few central nerve side effects. This innovative drug is currently undergoing a double-blind Phase III study in China for the treatment of post-herpes neuralgia, further validating its potential therapeutic benefits.
Neuropathic Pain Landscape
Neuropathic pain, caused by damage or pathological changes to the nervous system, is characterized by hyperalgesia, spontaneous pain, and abnormal pain. Due to the diversity of causes, its pathogenesis remains incompletely understood. While pregabalin is currently available to treat peripheral neurogenic pain in China, it is not approved for DPNP. HSK16149 aims to address this unmet need, offering a potential new treatment option for patients suffering from diabetic peripheral neuropathic pain.-Fineline Info & Tech
